Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Open Access
- 31 January 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (3), 567-574
- https://doi.org/10.1158/1078-0432.ccr-15-0321
Abstract
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) trametinib were analyzed to determine the association between BRAF mutation status in cfDNA and tumor tissue, and the association of BRAF cfDNA mutation status with baseline factors and clinical outcome.Keywords
Other Versions
This publication has 27 references indexed in Scilit:
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerThe New England Journal of Medicine, 2013
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II studyBritish Journal of Cancer, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic MelanomaThe Journal of Molecular Diagnostics, 2007
- Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving BiochemotherapyClinical Cancer Research, 2007
- Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patientsInternational Journal of Cancer, 2007
- Circulating nucleic acids (CNAs) and cancer—A surveyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2007
- Mutations of the BRAF gene in human cancerNature, 2002